Literature DB >> 10768427

Where next with stem-cell-supported high-dose therapy for breast cancer?

J Bergh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10768427     DOI： 10.1016/S0140-6736(00)90007-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Ethical issues in autologous stem cell transplantation (ASCT) in advanced breast cancer: a systematic literature review.

Authors:  Sigrid Droste; Annegret Herrmann-Frank; Fueloep Scheibler; Tanja Krones
Journal:  BMC Med Ethics       Date:  2011-04-15       Impact factor: 2.652

2.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.

Authors:  Yudi Pawitan; Judith Bjöhle; Lukas Amler; Anna-Lena Borg; Suzanne Egyhazi; Per Hall; Xia Han; Lars Holmberg; Fei Huang; Sigrid Klaar; Edison T Liu; Lance Miller; Hans Nordgren; Alexander Ploner; Kerstin Sandelin; Peter M Shaw; Johanna Smeds; Lambert Skoog; Sara Wedrén; Jonas Bergh
Journal:  Breast Cancer Res       Date:  2005-10-03       Impact factor: 6.466

Review 3.  Whither high-dose chemotherapy in breast cancer?

Authors:  A Mayer; H Earl
Journal:  Breast Cancer Res       Date:  2000-11-08       Impact factor: 6.466

4.  CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance.

Authors:  Tian Gao; Yong Han; Ling Yu; Sheng Ao; Ziyu Li; Jiafu Ji
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.